Data from clinical validation in the Netherlands selected for oral presentation at ESMO 2025
OSLO – September 4, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, is pleased to announce that The European Society for Medical Oncology (ESMO) has selected an interim analysis of a Dutch patient cohort for oral presentation. The study documents the prognostic value of Histotype Px® Colorectal in patients with high-risk stage II–III colon cancer who did not receive adjuvant chemotherapy (ACT). The presentation will take place at the ESMO Congress 2025 in Berlin on Monday October 20.
The interim results from a nationwide validation study shows analysis of 453 patients across 65 hospitals in the Netherlands. The aim is to demonstrate Histotype Px® Colorectal’s potential as a readily available and affordable AI digital biomarker to support personalized treatment decisions, reducing the number of patients exposed to futile ACT while identifying those who may need intensified treatment. The study is being performed in collaboration with UMC Utrecht and the Institute for Cancer Genetics and Informatics at Oslo University Hospital.
Torbjørn Furuseth, CEO and Co-founder of DoMore Diagnostics:
"The selection of this study for oral presentation at ESMO 2025 underlines the growing importance and recognition of AI-powered digital biomarkers as a transformative diagnostic modality in oncology. Histotype Px® is designed to be implemented on digitized routine histology slides, making it widely accessible and scalable."
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com